PMID- 36035926 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220830 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 9 DP - 2022 TI - Long-term prognostic value of macrophage migration inhibitory factor in ST-segment elevation myocardial infarction patients with metabolic syndrome after percutaneous coronary intervention. PG - 947395 LID - 10.3389/fcvm.2022.947395 [doi] LID - 947395 AB - Metabolic syndrome (MetS) is a major risk factor for cardiovascular disease and negatively affecting the prognosis of patients with ST elevation myocardial infarction (STEMI). Macrophage migration inhibitory factor (MIF) is a multipotent cytokine involved in various cardiovascular and inflammatory diseases. In this prospective study, we investigate the value of MIF in the long-term prognosis of STEMI combined with MetS after emergency PCI. Circulating MIF levels were measured at admission, and major adverse cardiovascular and cerebrovascular events (MACCE) were monitored during the follow-up period of 4.9 (3.9-5.8) years. MACCE occurred in 92 patients (22.9%), which was significantly higher in MetS (69/255, 27.1%) than in the non-MS subgroup (23/146, 15.8%, P < 0.05). Patients with MetS developed MACCE had the highest admission MIF level. Kaplan-Meier survival analysis using the cutoff value of admission MIF (143 ng/ml) showed that patients with a higher MIF level had a greater incidence of MACCE than those with lower MIF levels in both the MetS (P < 0.0001) and non-MetS groups (P = 0.016). After adjustment for clinical variables, the value of MIF >/= 143 ng/ml still had the predictive power for the MetS group [HR 9.56, 95% CI (5.397-16.944),P < 0.001]; nevertheless, it was not the case in the non-MetS group. Our findings indicated that MetS is a critical risk factor for adverse clinical outcomes in patients with STEMI, and a high admission MIF level has predictive power for the long-term MACCE, which is superior in STEMI patients with MetS and better than other traditional predictors. CI - Copyright (c) 2022 Yu, Zhao, Liu, Yuan, Fang, Zhang, Li, Li, Du, Gao and Yang. FAU - Yu, Xiao-Lin AU - Yu XL AD - Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. FAU - Zhao, Qian AU - Zhao Q AD - Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. AD - Xinjiang Key Laboratory of Cardiovascular Disease Research, Clinical Medical Research Institute of First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. FAU - Liu, Fen AU - Liu F AD - Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. AD - Xinjiang Key Laboratory of Cardiovascular Disease Research, Clinical Medical Research Institute of First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. FAU - Yuan, Yu-Juan AU - Yuan YJ AD - Department of Cardiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China. FAU - Fang, Bin-Bin AU - Fang BB AD - Xinjiang Key Laboratory of Cardiovascular Disease Research, Clinical Medical Research Institute of First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. FAU - Zhang, Xue-He AU - Zhang XH AD - Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. AD - Xinjiang Key Laboratory of Cardiovascular Disease Research, Clinical Medical Research Institute of First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. FAU - Li, Wen-Ling AU - Li WL AD - Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. AD - Xinjiang Key Laboratory of Cardiovascular Disease Research, Clinical Medical Research Institute of First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. FAU - Li, Xiao-Mei AU - Li XM AD - Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. AD - Xinjiang Key Laboratory of Cardiovascular Disease Research, Clinical Medical Research Institute of First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. FAU - Du, Guo-Li AU - Du GL AD - Department of Endocrinology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. AD - Xinjiang Key Laboratory of Medical Animal Model Research, Urumqi, China. FAU - Gao, Xiao-Ming AU - Gao XM AD - Xinjiang Key Laboratory of Cardiovascular Disease Research, Clinical Medical Research Institute of First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. AD - Xinjiang Key Laboratory of Medical Animal Model Research, Urumqi, China. AD - State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asian, Urumqi, China. FAU - Yang, Yi-Ning AU - Yang YN AD - Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. AD - Xinjiang Key Laboratory of Cardiovascular Disease Research, Clinical Medical Research Institute of First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. AD - Department of Cardiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China. AD - State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asian, Urumqi, China. LA - eng PT - Journal Article DEP - 20220811 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC9403533 OTO - NOTNLM OT - MACCE OT - ST- segment elevation myocardial infarction OT - coronary artery disease OT - macrophage migration inhibitory factor OT - metabolic syndrome COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/08/30 06:00 MHDA- 2022/08/30 06:01 PMCR- 2022/01/01 CRDT- 2022/08/29 05:33 PHST- 2022/05/18 00:00 [received] PHST- 2022/07/20 00:00 [accepted] PHST- 2022/08/29 05:33 [entrez] PHST- 2022/08/30 06:00 [pubmed] PHST- 2022/08/30 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2022.947395 [doi] PST - epublish SO - Front Cardiovasc Med. 2022 Aug 11;9:947395. doi: 10.3389/fcvm.2022.947395. eCollection 2022.